Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 55 (5), 2390-4

Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination With Tazobactam Against Enterobacteriaceae, Pseudomonas Aeruginosa, and Bacteroides Fragilis Strains Having Various Resistance Phenotypes

Affiliations

Antimicrobial Activity of CXA-101, a Novel Cephalosporin Tested in Combination With Tazobactam Against Enterobacteriaceae, Pseudomonas Aeruginosa, and Bacteroides Fragilis Strains Having Various Resistance Phenotypes

Helio S Sader et al. Antimicrob Agents Chemother.

Abstract

CXA-101, a novel oxyimino-aminothiazolyl cephalosporin, CXA-201 (CXA-101 combined with tazobactam), and various comparators were susceptibility tested by broth microdilution methods against 1,301 well-characterized clinical strains collected worldwide, including ceftazidime-resistant members of the family Enterobacteriaceae and Klebsiella pneumoniae carbapenemase (KPC)- and extended-spectrum β-lactamase (ESBL)-producing strains of Pseudomonas aeruginosa and Bacteroides fragilis. CXA-201 was 2- to 32-fold more active than ceftazidime and piperacillin-tazobactam against ceftazidime-resistant Enterobacteriaceae species but less active than cefepime for some species. CXA-101 and CXA-201 were very active against P. aeruginosa (MIC50, 1 μg/ml for both compounds), including imipenem-resistant strains.

Similar articles

See all similar articles

Cited by 38 PubMed Central articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources

Feedback